With Nanopore Sensing Beyond Sequencing, Ontera Takes 'Lab' to the Field

We’ve interviewed several CEOs over the years since the Theranos fiasco who avoided any mention of the blighted company whenever the comparison came up. But today’s guest, Murielle Thinard McLane, the CEO of Ontera, jumped at the chance before Theral could get to it.

"Some people might say, well that's the Theranos model. They (Theranos) didn't get it wrong. The demand for a fast, comprehensive point-of-care solution near the patient is there. Where they got it wrong is that you need a technology that is sound to do that!"

This is a public episode. If you’d like to discuss this with other subscribers or get access to bonus episodes, visit www.mendelspod.com/subscribe